Thierry Poynard

Thierry Poynard

Auto-generated profile, based on publicly available information

Thierry Poynard

APHP, Hepatol, Paris, France

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1997 in The Lancet
Verified
Journal Article
Closed access
TPThierry Poynard
Thierry Poynard
PBPierre Bedossa
Pierre Bedossa
POPierre Opolon
Pierre Opolon

1 June 2005 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
VRVlad Ratziu
Vlad Ratziu
FCFrédéric Charlotte
Frédéric Charlotte
AHAgnès Heurtier
Agnès Heurtier
SGSophie Gombert
Sophie Gombert
PGPhilippe Giral
Philippe Giral
LGLIDO Study Group
LIDO Study Group

1 October 1998 in The Lancet
Verified
Journal Article
Closed access
TPThierry Poynard
Thierry Poynard
PMPatrick Marcellin
Patrick Marcellin
SLSamuel S Lee
Samuel S Lee
CNChristian Niederau
Christian Niederau
GMGerald S Minuk
Gerald S Minuk
JAJanice Albrecht
Janice Albrecht

1 April 2001 in The Lancet
Verified
Journal Article
Closed access
FIF Imbert-Bismut
F Imbert-Bismut
VRV Ratziu
V Ratziu
LPL Pieroni
L Pieroni
FCF Charlotte
F Charlotte
YBY Benhamou
Y Benhamou
MGMULTIVIRC Group
MULTIVIRC Group

1 October 1999 in Hepatology
Verified
Journal Article
Open access
PDF file
YBYves Benhamou
Yves Benhamou
MBMarie Bochet
Marie Bochet
VMVincent Di Martino
Vincent Di Martino
FCFrederic Charlotte
Frederic Charlotte
FAFelipe Azria
Felipe Azria
FGfor the MULTIVIRC Group
for the MULTIVIRC Group
The natural history of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected patients has never been studied according to the concept of liver fibrosis progression. The aim of this work was to assess the fibrosis progression rate in HIV-HCV coinfected patients and in patients infected by HCV only. A cohort of 122 HIV-HCV coinfected patients was compared with a control group of 122 HIV-negative HCV-infected patients. Groups were matched according to age, sex, daily alcohol consumption, age at HCV infection, and duration and route of HCV infection. The fibrosis progression rate was defined as the ratio between fibrosis stage (METAVIR scoring system) and the HCV duration. The prevalence of extensive liver fibrosis (METAVIR fibrosis scores 2, 3, and 4) and moderate or severe activity were higher in HIV-infected patients (60% and 54%, respectively) than in control patients (47% and 30%, respectively; P < .05 and P < .001, respectively). The median fibrosis progression rate in coinfected patients and in control patients was 0.153 (95% confidence interval [CI], 0.117-0.181) and 0.106 (95% CI, 0.084-0.125) fibrosis units per year, respectively (P < .0001). HIV seropositivity (P < .0001), alcohol consumption (>50 g/d, P = .0002), age at HCV infection (<25 years old,P< .0001), and severe immunosuppression (CD4 count ≤200 cells/μL,P< .0001) were associated with an increase in the fibrosis progression rate. In coinfected patients, alcohol consumption (>50 g/d), CD4 count (≤200 cells/μL), and age at HCV infection (<25 years old) (P< .0001, respectively) were associated with a higher fibrosis progression rate. HIV seropositivity accelerates HCV-related liver fibrosis progression. In coinfected patients, a low CD4 count, alcohol consumption rate, and age at HCV infection are associated with a higher liver fibrosis progression rate.

1 May 2002 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
TPThierry Poynard
Thierry Poynard
JMJohn McHutchison
John McHutchison
MMMichael Manns
Michael Manns
CTChristian Trepo
Christian Trepo
KLKaren Lindsay
Karen Lindsay
JAJanice Albrecht
Janice Albrecht